Erythropoietin

Random entry RSS

Posted in:
Legal

Litigation Spotlight Update: The Epoetin alfa (Epogen®) Litigation
By Spencer Johnson August 2, 2017 Comments are off
Since our prior article on the litigation between Amgen and Hospira over Hospira’s proposed biosimilar to Amgen’s Epogen®, there have...

Read more

Tagged with: Amgen, Amgen v. Hospira, BPCIA, District Court, epoetin alfa, Epogen®, Erythropoietin, Featured, Federal Circuit, Hospira, Janssen, Legal, Litigation, Litigation Spotlight, Notice Requirement, Patent Dance, Pfizer, Procrit®, Retacrit®, Supreme Court

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
Legal

Litigation Spotlight: The Epoetin alfa (Epogen®) Litigation
By Spencer Johnson June 5, 2017 Comments are off
Introduction The Amgen, Inc. and Amgen Manufacturing, Limited (“Amgen”) litigation against Hospira, Inc. (“Hospira”), filed in...

Read more

Tagged with: Amgen, Amgen v. Hospira, BPCIA, District Court, epoetin alfa, Epogen®, Erythropoietin, Featured, Federal Circuit, Hospira, Janssen, Legal, Litigation, Notice Requirement, Patent Dance, Pfizer, Procrit®, Retacrit®, Supreme Court

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus

Back to Top